PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color (Q34660907)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color |
scientific article |
Statements
1 reference
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color (English)
1 reference
Meinolf Karthaus
1 reference
Lee S Schwartzberg
1 reference
Fernando Rivera
1 reference
Gianpiero Fasola
1 reference
Jean-Luc Canon
1 reference
J Randolph Hecht
1 reference
Hua Yu
1 reference
Kelly S Oliner
1 reference
William Y Go
1 reference
31 March 2014
1 reference
1 reference
Identifiers
1 reference